Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Altimmune, Inc. on June 9, 2017. The filing addresses Item 8.01 (Other Events) regarding the scheduling of the Company's 2017 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notification and does not contain financial performance data.
Material Changes
The primary material change disclosed is the rescheduling of the 2017 Annual Meeting of Stockholders. The meeting is now anticipated to occur on September 7, 2017, which is more than 30 days later than the one-year anniversary of the 2016 Annual Meeting. Consequently, the deadlines for stockholder proposals and director nominations have been adjusted.
Guidance, Outlook, and Corporate Actions
- Record Date: The Board of Directors set July 31, 2017, as the record date for stockholders entitled to notice of and to vote at the 2017 Annual Meeting.
- Meeting Date: The 2017 Annual Meeting is anticipated to be held on September 7, 2017.
- Proposal Deadlines: Due to the change in meeting date, stockholders wishing to submit proposals under Rule 14a-8 or director nominations under the Company's Bylaws must ensure written notice is received by the close of business on June 20, 2017.
- Submission Address: Proposals and nominations must be delivered to the Corporate Secretary at 19 Firstfield Road, Suite 200, Gaithersburg, Maryland 20878.
Key Facts for Investor Verification
- Verify the final date and location of the 2017 Annual Meeting in the upcoming proxy materials.
- Confirm the June 20, 2017, deadline for submitting stockholder proposals or director nominations to ensure eligibility.
- Note that the record date for voting eligibility is July 31, 2017.